Anti-PNPLA6 monoclonal antibody
Pre-made anti-PNPLA6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to PNPLA6/PNPLA6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0156-Ab-1/ GM-Tg-hg-IP0156-Ab-2 | Anti-Human PNPLA6 monoclonal antibody | Human |
GM-Tg-rg-IP0156-Ab-1/ GM-Tg-rg-IP0156-Ab-2 | Anti-Rat PNPLA6 monoclonal antibody | Rat |
GM-Tg-mg-IP0156-Ab-1/ GM-Tg-mg-IP0156-Ab-2 | Anti-Mouse PNPLA6 monoclonal antibody | Mouse |
GM-Tg-cynog-IP0156-Ab-1/ GM-Tg-cynog-IP0156-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PNPLA6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0156-Ab-1/ GM-Tg-felg-IP0156-Ab-2 | Anti-Feline PNPLA6 monoclonal antibody | Feline |
GM-Tg-cang-IP0156-Ab-1/ GM-Tg-cang-IP0156-Ab-2 | Anti-Canine PNPLA6 monoclonal antibody | Canine |
GM-Tg-bovg-IP0156-Ab-1/ GM-Tg-bovg-IP0156-Ab-2 | Anti-Bovine PNPLA6 monoclonal antibody | Bovine |
GM-Tg-equg-IP0156-Ab-1/ GM-Tg-equg-IP0156-Ab-2 | Anti-Equine PNPLA6 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0156-Ab-1/ GM-Tg-hg-IP0156-Ab-2; GM-Tg-rg-IP0156-Ab-1/ GM-Tg-rg-IP0156-Ab-2; GM-Tg-mg-IP0156-Ab-1/ GM-Tg-mg-IP0156-Ab-2; GM-Tg-cynog-IP0156-Ab-1/ GM-Tg-cynog-IP0156-Ab-2; GM-Tg-felg-IP0156-Ab-1/ GM-Tg-felg-IP0156-Ab-2; GM-Tg-cang-IP0156-Ab-1/ GM-Tg-cang-IP0156-Ab-2; GM-Tg-bovg-IP0156-Ab-1/ GM-Tg-bovg-IP0156-Ab-2; GM-Tg-equg-IP0156-Ab-1/ GM-Tg-equg-IP0156-Ab-2 |
Products Name | Anti-PNPLA6 monoclonal antibody |
Format | mab |
Target Name | PNPLA6 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-PNPLA6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0156-Ag-1 | Recombinant multi-species PLPL6/ PNPLA6/ BNHS protein |
Target information
Target ID | GM-IP0156 |
Target Name | PNPLA6 |
Gene ID | 10908,50767,360753,100426338,484993,101097705,767822,100060640 |
Gene Symbol and Synonyms | BNHS,iPLA2delta,LNMS,MSws,NTE,NTEMND,OMCS,PNPLA6,RGD1564611,SPG39,sws |
Uniprot Accession | Q8IY17 |
Uniprot Entry Name | PLPL6_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000032444 |
Target Classification | N/A |
The target: PNPLA6, gene name: PNPLA6, also named as BNHS, LNMS, NTE, NTEMND, OMCS, SPG39, iPLA2delta, sws. This gene encodes a phospholipase that deacetylates intracellular phosphatidylcholine to produce glycerophosphocholine. It is thought to function in neurite outgrowth and process elongation during neuronal differentiation. The protein is anchored to the cytoplasmic face of the endoplasmic reticulum in both neurons and non-neuronal cells. Mutations in this gene result in autosomal recessive spastic paraplegia, and the protein is the target for neurodegeneration induced by organophosphorus compounds and chemical warfare agents. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.